What Is D’OXYVA?


The D’OXYVA® device is a simple, commercially available medical device to deliver transdermal carbon dioxide (CO2). It consists of a patented and patent-pending ergonomic polymer shell that is propelled by a patented  steel pressurized cylinder filled with pharmaceutical-grade (USP) liquid, ultra-purified CO2. The mini steel cylinder (14.5 grams) is cGMP-compliant and recyclable.

D’OXYVA was categorized by the Western Institutional Review Board (WIRB) in successful human clinical studies as a non-significant risk (NSR) device.

The D’OXYVA device is manufactured in the United States and other countries. D’OXYVA is an ISO-compliant device, which means that Circularity Healthcare, LLC has received a certification that D’OXYVA fulfills all of the international requirements for medical device regulations, such as risk assessment and maintaining effective processes for safe design, manufacturing, and distribution. 

D’OXYVA (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, transdermal (over-the-skin) microcirculatory solution.

With over five years of industry-leading clinical research results, D’OXYVA demonstrated that it does not break the skin’s barrier while it provides outsized quality of life and clinical outcomes quickly and affordably. 

In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA is leading the field by: 

Significantly lowering the risk of diabetes, cardiovascular, and other major complications;

Providing complete healing of non-healing chronic wounds together with complete and long-term pain relief coupled with significantly improved quality of life.

D’OXYVA‘s gentle vapor solution with purified medical CO2 readily dissolves in a molecular form in the skin, acting as a catalyst to improve skin perfusion pressure and optimize nerve functions and microcirculation. 

Non-electrical, handheld, painless

Fast & easy use virtually anywhere

Learn how to use D’OXYVA

You may inquire about pricing on our Shop Page.

Who is involved in improving health care for patients?

COis the protagonist in D’OXYVA®’s revolutionary approach to improving health care and patients’ quality of life. The medical device causes controlled ischemia-like stress in a local area of the body to promote central nervous system activity and circulate humoral agents that favor microcirculation, especially at the organ capillary beds. Adequate blood flow in the capillary bed is essential for tissue survival and optimal organ function. If blood passes too quickly or does not pass at all, the tissue cannot extract Oefficiently and will generate what is known as capillary dysfunction, which is related to chronic pain, poor wound healing, diabetic neuropathy, and Alzheimer’s disease, among other conditions.

Where does COvapor delivered through the skin take action in the body?

Transdermal delivery of COhas proven to improve local microcirculation (capillary beds) blood flow and tissue perfusion, but it also positively improves systemic blood pressure and TcpO(most likely due to the Bohr Effect). As mentioned before, therapeutic medical-grade COis used for vasodilatation in the medical field for several conditions and procedures.
Local COtherapy has shown great success in improving the health care of patients through the following:

  • Treatment for diabetic foot
  • Increased microcirculation blood flow and dissociated Oin healthy and diabetic individuals
  • Treatment for arterial stenosis obliterans
  • Chronic wound healing
  • Adipose tissue treatment

Systemically, COtherapy has shown great success in improving the following:

  • The health care of patients with high blood pressure
  • General vital organ function, such as that of the:

– Pancreas – Liver – Brain – Kidneys

We are currently working with clinical researchers who are interested in participating in clinical trials with D’OXYVA®. Our goal is to produce exceptionally strong scientific evidence for D’OXYVA’s potential to radically improve health care. Please send us a message if you are interested to participate.

Latest Breakthroughs

The Blog.

Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)

PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the

Switch To D'OXYVA®.

The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.

D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.

Get in touch to avail D’OXYVA® for rapid chronic wound treatment.